Sarepta Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sarepta Therapeutics (US): 3 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and $3,200,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($3,200,000 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sarepta Therapeutics across sibling Meru public-data platforms.